New drug cocktail aims to shrink Hard-to-Treat lung tumors
NCT ID NCT06512051
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called SHR-A2102 combined with the immunotherapy adebrelimab, with or without chemotherapy or bevacizumab, in 248 people with advanced or metastatic non-small cell lung cancer. The goal is to find the safest dose and see if the combination can shrink tumors. Participants must have measurable tumors and provide a tissue sample.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-A2102 (a targeted drug) combined with adebrelimab (an immunotherapy), plus possible chemotherapy or bevacizumab
- What this could lead to
- If successful, this could offer a new treatment option for people with advanced lung cancer that has stopped responding to other therapies.
- What could go wrong
- This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug combo may not work or could cause serious side effects. It is not yet proven to be safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese People's Liberation Army General Hospital
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Morning or afternoon? new study tests if immunotherapy timing boosts cancer fight
- New pfizer drug shows promise against tough cancers
- New hope for advanced lung cancer: drug cocktails under trial
- New shot may simplify lung cancer treatment, phase 3 trial underway
- New combo aims to outperform chemo in tough lung cancers
- Lung cancer trial tests cocktail of new drugs against standard care